| Biosimilar infliximab market shares in Swedish counties ranged from 18 to 96% in 2017. |
| Variations in the discounted price difference between the biosimilar and originator product, and associated savings, explain variations in biosimilar uptake between counties. |
| Counties employ different strategies to achieve low costs for treatment with infliximab. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.